BACKGROUND: We sought to characterize the impact that hepatitis C virus (HCV) infection has on CD4 cells during the first 48 weeks of antiretroviral therapy (ART) in previously ART-naive human immunodeficiency virus (HIV)-infected patients. METHODS: The HIV/AIDS Drug Treatment Programme at the British Columbia Centre for Excellence in HIV/AIDS distributes all ART in this Canadian province. Eligible individuals were those whose first-ever ART included 2 nucleoside reverse transcriptase inhibitors and either a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor and who had a documented positive result for HCV antibody testing. Outcomes were binary events (time to an increase of > or = 75 CD4 cells/mm3 or an increase of > or = 10% in the percentage of CD4 cells in the total T cell population [CD4 cell fraction]) and continuous repeated measures. Statistical analyses used parametric and nonparametric methods, including multivariate mixed-effects linear regression analysis and Cox proportional hazards analysis. RESULTS: Of 1186 eligible patients, 606 (51%) were positive and 580 (49%) were negative for HCV antibodies. HCV antibody-positive patients were slower to have an absolute (P<.001) and a fraction (P = .02) CD4 cell event. In adjusted Cox proportional hazards analysis (controlling for age, sex, baseline absolute CD4 cell count, baseline pVL, type of ART initiated, AIDS diagnosis at baseline, adherence to ART regimen, and number of CD4 cell measurements), HCV antibody-positive patients were less likely to have an absolute CD4 cell event (adjusted hazard ratio [AHR], 0.84 [95% confidence interval [CI], 0.72-0.98]) and somewhat less likely to have a CD4 cell fraction event (AHR, 0.89 [95% CI, 0.70-1.14]) than HCV antibody-negative patients. In multivariate mixed-effects linear regression analysis, HCV antibody-negative patients had increases of an average of 75 cells in the absolute CD4 cell count and 4.4% in the CD4 cell fraction, compared with 20 cells and 1.1% in HCV antibody-positive patients, during the first 48 weeks of ART, after adjustment for time-updated pVL, number of CD4 cell measurements, and other factors. CONCLUSION: HCV antibody-positive HIV-infected patients may have an altered immunologic response to ART.
BACKGROUND: We sought to characterize the impact that hepatitis C virus (HCV) infection has on CD4 cells during the first 48 weeks of antiretroviral therapy (ART) in previously ART-naive human immunodeficiency virus (HIV)-infectedpatients. METHODS: The HIV/AIDS Drug Treatment Programme at the British Columbia Centre for Excellence in HIV/AIDS distributes all ART in this Canadian province. Eligible individuals were those whose first-ever ART included 2 nucleoside reverse transcriptase inhibitors and either a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor and who had a documented positive result for HCV antibody testing. Outcomes were binary events (time to an increase of > or = 75 CD4 cells/mm3 or an increase of > or = 10% in the percentage of CD4 cells in the total T cell population [CD4 cell fraction]) and continuous repeated measures. Statistical analyses used parametric and nonparametric methods, including multivariate mixed-effects linear regression analysis and Cox proportional hazards analysis. RESULTS: Of 1186 eligible patients, 606 (51%) were positive and 580 (49%) were negative for HCV antibodies. HCV antibody-positive patients were slower to have an absolute (P<.001) and a fraction (P = .02) CD4 cell event. In adjusted Cox proportional hazards analysis (controlling for age, sex, baseline absolute CD4 cell count, baseline pVL, type of ART initiated, AIDS diagnosis at baseline, adherence to ART regimen, and number of CD4 cell measurements), HCV antibody-positive patients were less likely to have an absolute CD4 cell event (adjusted hazard ratio [AHR], 0.84 [95% confidence interval [CI], 0.72-0.98]) and somewhat less likely to have a CD4 cell fraction event (AHR, 0.89 [95% CI, 0.70-1.14]) than HCV antibody-negative patients. In multivariate mixed-effects linear regression analysis, HCV antibody-negative patients had increases of an average of 75 cells in the absolute CD4 cell count and 4.4% in the CD4 cell fraction, compared with 20 cells and 1.1% in HCV antibody-positive patients, during the first 48 weeks of ART, after adjustment for time-updated pVL, number of CD4 cell measurements, and other factors. CONCLUSION:HCV antibody-positive HIV-infectedpatients may have an altered immunologic response to ART.
Authors: R Oyomopito; M P Lee; P Phanuphak; P L Lim; R Ditangco; J Zhou; T Sirisanthana; Y M A Chen; S Pujari; N Kumarasamy; S Sungkanuparph; C K C Lee; A Kamarulzaman; S Oka; F J Zhang; C V Mean; T Merati; G Tau; J Smith; P C K Li Journal: HIV Med Date: 2010-03-21 Impact factor: 3.180
Authors: David M Moore; Ross Harris; Viviane Lima; Bob Hogg; Margaret May; Benita Yip; Amy Justice; Amanda Mocroft; Peter Reiss; Fiona Lampe; Geneviève Chêne; Dominique Costagliola; Luigia Elzi; Michael J Mugavero; Antonella D'Arminio Monforte; Caroline Sabin; Daniel Podzamczer; Gerd Fätkenheuer; Schlomo Staszewski; John Gill; Jonathan A C Sterne Journal: J Acquir Immune Defic Syndr Date: 2009-11-01 Impact factor: 3.731
Authors: Debbie M Cheng; David Nunes; Howard Libman; John Vidaver; Julie K Alperen; Richard Saitz; Jeffrey H Samet Journal: Alcohol Clin Exp Res Date: 2007-03-31 Impact factor: 3.455
Authors: Maria C Villacres; Naoko Kono; Wendy J Mack; Marek J Nowicki; Kathryn Anastos; Michael Augenbraun; Chenglong Liu; Alan Landay; Ruth M Greenblatt; Stephen J Gange; Alexandra M Levine Journal: J Infect Dis Date: 2012-06-12 Impact factor: 5.226
Authors: Félix Gutierrez; Sergio Padilla; Mar Masiá; José A Iribarren; Santiago Moreno; Pompeyo Viciana; Leopoldo Muñoz; José L Gómez Sirvent; Francesc Vidal; José López-Aldeguer; José R Blanco; Manuel Leal; María Angeles Rodríguez-Arenas; Santiago Perez Hoyos Journal: PLoS One Date: 2006-12-20 Impact factor: 3.240